Table 1 Baseline characteristics of 85 patients with advanced hepatocellular carcinoma who received atezolizumab plus bevacizumab
Characteristic | N = 85 |
|---|---|
Sex, male, n (%) | 73 (85.9) |
Age > 74, n (%) | 41 (48.2) |
HBV positive, n (%) | 18 (21.2) |
HCV positive, n (%) | 25 (29.4) |
Child–Pugh class A, n (%) | 79 (92.9) |
AFP > 400 ng/mL, n (%) | 32 (37.6) |
BCLC stage C, n (%) | 52 (61.2) |
Macrovascular invasion, n (%) | 18 (21.2) |
Extrahepatic spread, n (%) | 35 (41.2) |
Treatment line, atezolizumab plus bevacizumab,1st line, n (%) | 39 (45.9) |
ECOG-PS ≤ 1, n (%) | 85 (100) |
NLR ≥ 3.43, n (%) | 35 (41.2) |